Last reviewed · How we verify
LW231
At a glance
| Generic name | LW231 |
|---|---|
| Sponsor | Shanghai Longwood Biopharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of LW231 in Participants With Chronic Hepatitis B (PHASE1, PHASE2)
- A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LW231 CI brief — competitive landscape report
- LW231 updates RSS · CI watch RSS
- Shanghai Longwood Biopharmaceuticals Co., Ltd. portfolio CI